Om

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting unmet needs in immune-mediated diseases. Its lead product candidate, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor currently in clinical trials for indications such as lupus nephritis, dermatomyositis, polymyositis, and systemic lupus erythematosus. The company is also advancing KZR-261, a first-in-class protein secretion inhibitor aimed at treating tumors resistant to traditional chemotherapeutics. Kezar Life Sciences employs unique protein-targeting approaches, including selective immunoproteasome inhibition, to modulate the immune system in autoimmune diseases like autoimmune hepatitis, offering alternatives to direct immunosuppression. These therapies address critical gaps in treatment for chronic autoimmune conditions and oncology, positioning the company at the forefront of innovative immunology and cancer research. Incorporated in 2015 and headquartered in South San Francisco, California, Kezar Life Sciences continues to advance its pipeline through rigorous clinical development.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I KEZAR LIFE SCIENCES MED ENDAVU: Køb Kezar Life Sciences ($2KZ0) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Kezar Life Sciences, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.